• Platycodin D Induces Apoptosis via RFC4 and Notch Axis in NS

  2026-06-11

  Zhang et al. present a multidimensional proteomics study demonstrating that Platycodin D triggers apoptosis in non-small cell lung cancer (NSCLC) by binding to RFC4 and downregulating the Notch signaling pathway. This mechanistic insight highlights potential strategies for targeting epigenetic and proteostatic vulnerabilities in NSCLC.

• Fluorescein Tyramide: Amplifying Sensitivity in Brain Circui

  2026-06-10

  Fluorescein Tyramide enables ultrasensitive detection of low-abundance targets in neural circuit research, transforming immunohistochemistry and in situ hybridization workflows. Its robust signal amplification, as used in recent oxytocin signaling studies, empowers researchers to reveal subtle neurobiological changes that conventional dyes miss.

• 3X (DYKDDDDK) Peptide: Robust Tagging for Protein Purificati

  2026-06-10

  This article explores how the 3X (DYKDDDDK) Peptide (SKU A6001) streamlines recombinant protein workflows for biomedical labs, emphasizing protocol reproducibility, metal-dependent assay compatibility, and sensitivity in immunodetection. Practical Q&A scenarios highlight its unique advantages for affinity purification and data reliability.

• Cisplatin (CDDP): Applied Workflows and Troubleshooting in C

  2026-06-09

  Cisplatin (CDDP) powers precise apoptosis assays and robust tumor growth inhibition studies, thanks to its DNA crosslinking and unique apoptotic mechanisms. This guide distills advanced workflows, protocol enhancements, and troubleshooting insights for maximizing reproducibility and mechanistic clarity in cancer research.

• Fosinopril Sodium: Applied Workflows for ACE Inhibitor Resea

  2026-06-09

  Fosinopril sodium’s phosphinic acid scaffold sets it apart for researchers modeling hypertension and cardiovascular disease. This article delivers protocol-ready guidance, experimental enhancements, and troubleshooting strategies to maximize the compound’s translational impact in blood pressure and renal hemodynamics research.

• Pravastatin Sodium: Mechanistic Precision for Translational

  2026-06-08

  Explore how pravastatin sodium, a selective HMG-CoA reductase inhibitor, delivers mechanistic clarity and strategic opportunity for translational researchers tackling cardiovascular and metabolic disease. We synthesize recent hepatocyte findings, competitive insights, and practical workflow guidance to shape rigorous science and forward-looking protocols.

• 3-Deazaadenosine: Potent SAH Hydrolase Inhibitor for Antivir

  2026-06-08

  3-Deazaadenosine is a rigorously characterized S-adenosylhomocysteine hydrolase inhibitor used in preclinical antiviral and methylation research. Its mechanism suppresses SAM-dependent methyltransferase activity, impacting viral replication and epigenetic regulation. Verified in vitro and in vivo studies confirm its efficacy and utility for translational workflows.

• FDA-Approved Drugs Inhibit MERS-CoV Replication: Screening I

  2026-06-07

  This study systematically screened 348 FDA-approved compounds and identified four small molecules—chloroquine, chlorpromazine, loperamide, and lopinavir—that inhibit Middle East respiratory syndrome coronavirus (MERS-CoV) replication in cell culture. The findings highlight rapid repurposing potential for anticoronavirus therapies and inform future translational research.

• EZH2 Inhibition and 5-Azacytidine Synergize in PTEN-Deficien

  2026-06-06

  This paper reveals that PTEN-deficient glioblastoma sustains an immunosuppressive microenvironment by suppressing the ERV-MAVS-IFN pathway. Dual targeting with EZH2 inhibition and 5-Azacytidine reactivates viral mimicry and type I interferon signaling, offering a promising strategy to enhance antitumor immunity in this resistant cancer subtype.

• Fucoidan (C4038): Sulfated α-L-Fucan for Anticancer Research

  2026-06-05

  Fucoidan is a highly purified sulfated α-L-fucan derived from brown seaweed, exhibiting robust anticancer and immune-modulating activity. APExBIO's Fucoidan (C4038) demonstrates apoptosis induction in prostate and breast cancer models and suppresses angiogenesis, supported by multiple in vitro and in vivo studies. Its standardized purity and validated mechanisms make it a benchmark tool for oncology and immunology workflows.

• Syringin Enhances Sunitinib Response in RCC via EGFR/PI3K/Ak

  2026-06-05

  This study identifies Syringin as a promising natural product that inhibits renal cell carcinoma (RCC) growth and sensitizes cells to sunitinib by targeting the EGFR/PI3K/Akt pathway. The findings highlight Syringin’s mechanistic role in overcoming drug resistance and provide an evidence-driven rationale for integrating natural products into RCC therapeutic research.

• Cycloheximide: Protein Biosynthesis Inhibitor for Cell Resea

  2026-06-04

  Cycloheximide enables precise, rapid inhibition of protein synthesis, making it a gold-standard tool for dissecting apoptosis, protein turnover, and neuroprotection in cell and animal models. This guide delivers actionable workflows, troubleshooting strategies, and protocol enhancements to maximize data quality and reproducibility in advanced research.

• NF 449: Purinergic Receptor Antagonist Accelerates Platelet

  2026-06-04

  NF 449 stands out as a highly selective purinergic receptor antagonist, redefining platelet aggregation and antithrombotic research with unrivaled potency at the P2X1 ion channel. Discover how its application streamlines experimental workflows, enhances assay precision, and offers actionable troubleshooting insights for demanding platelet activation studies.

• Romidepsin (FK228): Epigenetic Mechanisms and Advanced Oncol

  2026-06-03

  Explore the scientific basis and research protocols for Romidepsin (FK228), a selective HDAC inhibitor pivotal in epigenetic modulation and cancer therapy research. This article delivers a deeper mechanistic analysis and practical guidance distinct from standard protocols.

• Protease Inhibitor Cocktail (EDTA-Free, 200X): Mechanisms &

  2026-06-03

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) from APExBIO is a broad-spectrum protein extraction protease inhibitor designed to stabilize cellular proteins during workflows such as Western blotting and co-immunoprecipitation. Its EDTA-free formulation maintains compatibility with kinase and phosphorylation assays, delivering robust protein degradation prevention for up to 48 hours in culture. This article details its mechanism, evidence base, and best-practice integration.

451 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page